Q2 FY2026 EarningsQ2 FY26 results for FBRX missed consensus on bottom-line metrics despite in-line zero revenue. Net loss reached $23.3M compared to an expected $22.7M, and GAAP EPS of -$0.97 missed the -$1.00 mean expectation by $0.03. The deviation was driven by R&D expenses swelling to $22.3M (+158% YoY) to support Phase 2 clinical trials. However, a significant upside was confirmed via the July 2026 merger agreement with argenx at $77.00 per share, representing a substantial premium over current trading levels.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Forte Biosciences(FBRX) the EBIT is -24.6 M (-112.5%), Miss estimate;the EPS is -0.97 (-1.04%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B112.48%
-0.02B95.73%
-0.00B16.75%
EPSExceed expectations
-0.971.04%
-1.00334.51%
+0.03333.47%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf